Added to YB: 2026-09-07
Pitch date: 2026-09-04
DRTS [bullish]
Alpha Tau Medical Ltd.
Author Info
Anders Research shares equity research primarily focused on micro/small/mid-cap biotechnology. We follow companies with mechanistically differentiated approaches to large market opportunities, with special focus in neuroscience. Sign up for the newsletter.
Company Info
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer.
Market Cap
$1.3B
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-26.68
P/E
-13.90
EV/Sales
N/A
Sector
Health Care Equipment and Supplies
Category
growth
Alpha Tau: Approaching Massive Year-End; Pounding the Table on Potential GBM Breakthrough
DRTS (added to position): Alpha Tau remains the most attractive risk/reward setup in the covered biotech universe, prompting continued additions in coming weeks despite a ~300% gain since initiation. The thesis changed after two complete responses and ~30% tumor shrinkage among the first three recurrent-GBM patients; similar results in the full 10-patient readout could accelerate the regulatory path. Key risks are the tiny, short-duration sample and potentially unusually resilient patients.
Read full article (16 min)